281 related articles for article (PubMed ID: 31253648)
1. Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab.
Oashi A; Yasuda H; Kobayashi K; Tani T; Hamamoto J; Masuzawa K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
Mol Cancer Ther; 2019 Sep; 18(9):1593-1601. PubMed ID: 31253648
[No Abstract] [Full Text] [Related]
2. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
3. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
Pirazzoli V; Ayeni D; Meador CB; Sanganahalli BG; Hyder F; de Stanchina E; Goldberg SB; Pao W; Politi K
Clin Cancer Res; 2016 Jan; 22(2):426-35. PubMed ID: 26341921
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
Sutandyo N; Hanafi A; Jayusman M
Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
[TBL] [Abstract][Full Text] [Related]
6. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
Arrieta O; Catalán R; Guzmán-Vazquez S; Barrón F; Lara-Mejía L; Soto-Molina H; Ramos-Ramírez M; Flores-Estrada D; de la Garza J
BMC Cancer; 2020 Sep; 20(1):829. PubMed ID: 32873256
[TBL] [Abstract][Full Text] [Related]
8. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
9. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
[TBL] [Abstract][Full Text] [Related]
11. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
Kwok WC; Ho JCM; Tam TCC; Ip MSM; Lam DCL
Thorac Cancer; 2022 Jul; 13(14):2057-2063. PubMed ID: 35668712
[TBL] [Abstract][Full Text] [Related]
12. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
13. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
Cancer Res Treat; 2023 Apr; 55(2):479-487. PubMed ID: 36596729
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
Hasegawa H; Yasuda H; Hamamoto J; Masuzawa K; Tani T; Nukaga S; Hirano T; Kobayashi K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
Lung Cancer; 2019 Jan; 127():146-152. PubMed ID: 30642543
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Zhang X; Maity T; Kashyap MK; Bansal M; Venugopalan A; Singh S; Awasthi S; Marimuthu A; Charles Jacob HK; Belkina N; Pitts S; Cultraro CM; Gao S; Kirkali G; Biswas R; Chaerkady R; Califano A; Pandey A; Guha U
Mol Cell Proteomics; 2017 May; 16(5):891-910. PubMed ID: 28331001
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
Janjigian YY; Smit EF; Groen HJ; Horn L; Gettinger S; Camidge DR; Riely GJ; Wang B; Fu Y; Chand VK; Miller VA; Pao W
Cancer Discov; 2014 Sep; 4(9):1036-45. PubMed ID: 25074459
[TBL] [Abstract][Full Text] [Related]
18. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
[TBL] [Abstract][Full Text] [Related]
19. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant
Udagawa H; Hasako S; Ohashi A; Fujioka R; Hakozaki Y; Shibuya M; Abe N; Komori T; Haruma T; Terasaka M; Fujita R; Hashimoto A; Funabashi K; Yasuda H; Miyadera K; Goto K; Costa DB; Kobayashi SS
Mol Cancer Res; 2019 Nov; 17(11):2233-2243. PubMed ID: 31467113
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]